Methods of treatment of cancer with reduced ubb expression
AssigneeNovartis AG
InventorsWilliam C. Forrester, Alexia T. Kedves-Volpe
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising a UBC antagonist and methods of use thereof for treating cancer in a patient. In some embodiments, the cancer patient may have a reduced expression level of a UBB gene product. Further provided are reagents and methods for detection of a UBB and/or UBC gene product.
Claims67
A method of treating cancer in a patient comprising:
- (a) identifying a patient having cancer with a reduced expression level of a ubiquitin B (UBB) gene product;
- and
- (b) administering to the patient a ubiquitin C (UBC) antagonist.
A method of treating cancer in a patient comprising:
- (a) identifying a patient having cancer with a ratio of an expression level of a ubiquitin C (UBC) gene product to an expression level of a ubiquitin B (UBB) gene product that is greater than 1.25;
- and
- (b) administering to the patient a UBC antagonist.
A method of treating a patient having cancer, comprising administering to the patient a therapeutically effective amount of a ubiquitin C (UBC) antagonist.
A method of sensitizing a patient having cancer for a chemotherapy treatment comprising administering to the patient a ubiquitin C (UBC) antagonist.
A pharmaceutical composition for treating cancer in a patient comprising a therapeutically effective amount of a ubiquitin C (UBC) antagonist and an excipient.
A pharmaceutical composition for use in treating cancer in a patient, characterized in that:
- (a) a patient is identified as having cancer with reduced expression level of a ubiquitin B (UBB) gene product or having a ratio of an expression level of a ubiquitin C (UBC) gene product to an expression level of a ubiquitin B (UBB) gene product that is greater than 1.25;
- and
- (b) a pharmaceutical composition comprising a therapeutically effective amount of a ubiquitin C (UBC) antagonist is administered to the patient.
A method of predicting or prognosing responsiveness to a treatment by a cancer patient, comprising:
- (a) contacting a sample from the cancer patient with a reagent that specifically binds to a ubiquitin B (UBB) gene or product thereof to form a binding complex;
- (b) measuring the amount of the binding complex;
- and
- (c) determining the responsiveness to the treatment by the cancer patient using the amount of the binding complex,
- wherein the treatment comprises administering a ubiquitin C (UBC) antagonist to the cancer patient.
Use of a reagent that specifically binds to a ubiquitin B (UBB) gene or product thereof for predicting or prognosing responsiveness to a treatment by a cancer patient, wherein the treatment comprises administering a ubiquitin C (UBC) antagonist to the cancer patient.
Dependencies are inferred from the claim text.